/**

Health X Platform in FY26: Growth Returns, But Profitability Still Lags

Health X Platform Limited, earlier known as Sastasundar Ventures, used its May 2026 investor presentation to sharpen its positioning as an AI-powered digital health platform built on two rails: a consumer app (SastaSundar) and a retailer enablement platform (RetailerShakti). The financials show that growth has re-accelerated in FY26, with revenue from operations rising to 1,305.9 crore, up 20.0% year on year. Gross profit improved to 97.5 crore and gross margin expanded to 7.5% from 6.5%.

But the presentation also highlights the gap between scale and profitability. FY26 EBITDA remained negative at 65.5 crore, translating to an EBITDA margin of -5.0%. Operating cash flow was also negative at -73.8 crore for the year ended March 2026. Even in Q4 FY26, when revenue grew 34.1% year on year to 378.1 crore, the quarter ended with a loss after tax of 12.9 crore.

The business mix is dominated by B2B distribution

The company discloses a revenue breakup by vertical to indicate order flows across platforms. For FY26, RetailerShakti contributed 1,125.4 crore, while SastaSundar contributed 155.5 crore. Diagnostics was still small at 2.2 crore for the year. Separately, financial services revenue was 94.4 crore. The deck notes that the entire revenue is treated as one segment, and the split is shared only to indicate orders of each platform, with SastaSundar operated by a step-down subsidiary.

This mix matters because it frames HealthX less as a pure B2C e-pharmacy story and more as a scaled distribution and fulfilment business with a digital interface. RetailerShakti, by itself, accounts for the bulk of the platform activity, reflecting the company’s strategy of anchoring growth in pharmacy and retailer relationships.

Operational metrics and working capital discipline

HealthX’s narrative is built on reach and efficiency. The presentation claims that 90% of orders follow a within 24 hours delivery model. It also lists scale indicators including 50,000 plus SKUs sourced from 700 plus vendors, 62,000 retail pharmacies on the network, 300 plus HealthBuddies, and 2,800 plus employees.

Working capital is one area where the deck provides specific and comparable data. For the quarter ended March 2026, working capital is shown at 18 days versus 23 days in March 2025. Working capital as a percent of revenue is shown at 5% in March 2026. Inventory days were stable around the mid-30s, while payables and receivables moved quarter to quarter.

This working capital performance is important because the business carries physical inventory and must fund rapid fulfilment. Any sustainable improvement in cash conversion will likely need to come from a combination of better gross margin, tighter inventory control, and supplier terms. FY26 results show that margin and working capital efficiency improved, but operating cash flow remained negative.

Capacity expansion is the core execution bet

The presentation highlights a network of fulfilment centres and positions the company’s scale as an enabler of profitable growth. A warehouse expansion table discloses existing capacity of about 221,300 square feet across West Bengal, Noida, and Guwahati, along with planned additional capacity of about 505,000 square feet. New fulfilment centres are planned in Lucknow, Udaipur, and Patna.

The company links this expansion to operational outcomes rather than only footprint. It states that facilities are automated with AI-led picking, sorting and routing. The stated benefits include lower manpower cost, higher throughput, and maximum delivery within 24 hours. It also notes that new fulfilment centres in Udaipur and Lucknow are intended to improve coverage across Northern India by decongesting Noida and reducing delivery lead times.

These claims make the fulfilment build-out the central test of execution. If capacity additions translate into faster delivery, lower unit costs, and higher service reliability, the company’s efficiency narrative could strengthen. If not, fixed costs can rise faster than margins in a low gross margin distribution model.

Strategy: growth, AI integration, and a push for cash generation

The company outlines strategic priorities for the next five years with three themes.

First, it states a target of 30% plus CAGR growth. The levers mentioned include expanding wallet share of existing customers, acquiring new customers, and penetrating more geographies through new fulfilment centres. It also mentions category expansion into wellness, personal care and beauty care, and adding services such as diagnostics, doctor consultation and quick health.

Second, it describes AI integration across the value chain. Use cases listed include intelligent medicine and diagnostic counselling, consultation validation for quality assurance, wellness counselling and personalized recommendations, smart health records with automated testing hooks, and backend process automation to enhance productivity.

Third, it highlights an intent to focus on profit and cash flow generation through revenue growth, gross margin expansion, operating cost optimization, and monetization of digital property. These are directionally useful priorities, but the presentation does not provide quantified margin targets, capex outlay guidance, or timelines for the commissioning of each fulfilment centre.

Takeaways for investors

Health X Platform’s FY26 presentation shows a company that has returned to growth, improved gross profit, and tightened working capital days. The core engine, RetailerShakti, continues to dominate the revenue base, reinforcing the company’s identity as a distribution and fulfilment-led health platform.

At the same time, profitability remains the key gap. FY26 EBITDA stayed negative and operating cash flow was negative, even as revenue rose. The next phase depends heavily on whether capacity expansion and automation can improve unit economics in a structurally low-margin category.

The story is clear: expand reach, use AI to lift service quality and productivity, and convert scale into cash generation. The numbers show progress on growth and gross margin, but the business still needs to prove that scale can translate into durable profitability. */